The ISI company compared to giants like Johnson & Pfizer is pitifully weak.
Compared to these, ISI and Eckes are more similar, both being companies with a single product, and their market values are not too high.
However, ISI's only advantage is that it has a longer history of development than Eckes, has passed the US FDA and 510K testing, and after attaining a monopolistic position, has developed smoothly to reach a scale of 4 billion US dollars.
Eckes, on the other hand, now only has a market value of less than 1.2 billion US dollars. After paying a large sum of money to Johnson, Eckes is really reeling, and to survive this winter, it must rely on the appearance of the x-pri guide.
The past two days, everyone in the guide design team suddenly discovered that Team Leader Chen had disappeared; upon careful searching, they found he had started playing with this "Octopus"!
Actually, performing Da Vinci robotic surgeries is not at all easier than hands-on operations.